Oral Propranolol for Hemangiomas of Infancy

Marcia L. Buck, Pharm.D., FCCP, FPPAG


Pediatr Pharm. 2010;16(8) 

In This Article


Based on the successful results of numerous case series, oral propranolol has earned a role as a first-line therapy in the management of infantile hemangiomas. Although controlled clinical trials are still underway, the efficacy of propranolol in reducing the size of facial, orbital, and airway hemangiomas, as well as its mild adverse effect profile, have made it a preferable choice over traditional treatments. Recent case reports have also suggested a potential role for propranolol in the management of hepatic hemangiomas and diffuse hemangiomatosis as well.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: